---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-116976"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2023-04-26T23:59:59+00:00"
generated_at: "2026-06-16T13:48:24.880032+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zymeworks to transfer zanidatamab program to Jazz; Jazz acquires ZZI subsidiary

## Summary
- On April 25, 2023, Zymeworks entered a Stock and Asset Purchase Agreement with Jazz Pharmaceuticals to transfer the zanidatamab program.
- Jazz will acquire 100% of ZZI, a Zymeworks subsidiary focused on zanidatamab, and related assets and employees.
- No Zymeworks common stock is sold; Jazz assumes responsibility for development and commercialization under an amended collaboration agreement.
- Zymeworks retains rights to ZW49 (zanidatamab zovodotin) and will continue to supply zanidatamab to clinical sites.
- Closing expected in May 2023; financial terms of the original collaboration agreement remain unchanged.

## SEC filing metadata
- accession: 0001193125-23-116976
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2023-04-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000119312523116976/0001193125-23-116976-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000119312523116976/d292152d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-116976
- JSON: https://secwatch.observer/filing/0001193125-23-116976.json
- Plain text: https://secwatch.observer/filing/0001193125-23-116976.txt

## Key facts
- Material Agreements
  Zymeworks Inc. entered into Stock and Asset Purchase Agreement with Jazz Pharmaceuticals, Inc. (effective 2023-04-25).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Jazz Pharmaceuticals, Inc.
  - Effective: 2023-04-25
  source text: On April 25, 2023, Zymeworks BC Inc. (“Zymeworks BC”), a subsidiary of Zymeworks Inc. (the “Company”), Zymeworks Biopharmaceuticals Inc. (“ZBI”), a subsidiary of Zymeworks BC, Zymeworks Zanidatamab Inc. (“ZZI”), a subsidiary of ZBI formed in December 2022 focused on the Company’s development program for the Company’s bispecific HER2 antibody product candidate known as zanidatamab, and Jazz Pharmaceuticals, Inc. (“Jazz”), entered into a Stock and Asset Purchase Agreement (the “Transfer Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937653/000119312523116976/0001193125-23-116976-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.